CSCIF (Cosciens Biopharma) Shiller PE Ratio: (As of Aug. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSCIF Cosciens Biopharma Inc CSCIF
61 GF Score
Price $5.50
GF Value $7.02
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cosciens Biopharma Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Cosciens Biopharma  (OTCPK:CSCIF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cosciens Biopharma Shiller PE Ratio Related Terms


Cosciens Biopharma Shiller PE Ratio Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Shiller PE Ratio Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 24.18 18.75 8.34 123.98 0.00

Cosciens Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CSCIF vs VRTX, REGN, RVMD: Shiller PE Ratio Comparison

For the Biotechnology subindustry, Cosciens Biopharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cosciens Biopharma Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cosciens Biopharma's Shiller PE Ratio falls into.


CSCIF
61GF Score
Cosciens Biopharma Inc CSCIF
Shiller PE Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cosciens Biopharma's E10 for the quarter that ended in Jun. 2026 is calculated as:

For example, Cosciens Biopharma's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.19/133.5265*133.5265
=-0.190

Current CPI (Jun. 2026) = 133.5265.

Cosciens Biopharma Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201609 0.967 101.765 1.269
201612 -0.106 101.449 -0.140
201703 0.022 102.634 0.029
201706 0.472 103.029 0.612
201709 0.397 103.345 0.513
201712 -2.036 103.345 -2.631
201803 -0.384 105.004 -0.488
201806 -0.211 105.557 -0.267
201809 -0.385 105.636 -0.487
201812 0.597 105.399 0.756
201903 -0.952 106.979 -1.188
201906 -0.968 107.690 -1.200
201909 -0.129 107.611 -0.160
201912 0.947 107.769 1.173
202003 0.896 107.927 1.109
202006 0.931 108.401 1.147
202009 0.231 108.164 0.285
202012 -0.855 108.559 -1.052
202103 1.007 110.298 1.219
202106 1.025 111.720 1.225
202109 0.997 112.905 1.179
202112 0.998 113.774 1.171
202203 2.036 117.646 2.311
202206 1.973 120.806 2.181
202209 0.930 120.648 1.029
202212 0.003 120.964 0.003
202303 -0.462 122.702 -0.503
202306 -1.410 124.203 -1.516
202309 -1.260 125.230 -1.343
202312 -2.550 125.072 -2.722
202403 -2.280 126.258 -2.411
202406 -1.920 127.522 -2.010
202409 -5.550 127.285 -5.822
202412 -7.050 127.364 -7.391
202503 -3.480 129.181 -3.597
202506 -2.570 129.892 -2.642
202509 -1.710 130.287 -1.753
202512 -2.040 130.366 -2.089
202603 8.700 132.262 8.783
202606 -0.190 133.527 -0.190

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $5.50 is trading 21.7% below its estimated GF Value™ of $7.02. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Shiller PE Ratio:
  • GF Value™: $7.02 vs. price of $5.50 (21.7% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score

Get the complete analysis for CSCIF

Shiller PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.50
Price
$7.02
GF Value